Literature DB >> 28120727

Antiplatelet Agents and Anticoagulants: From Pharmacology to Clinical Practice.

Maria E Tsoumani1, Alexandros D Tselepis2.   

Abstract

Thrombosis is the formation of potentially deadly blood clots in the artery (arterial thrombosis) or vein (venous thrombosis). Since thrombosis is one of the main causes of death worldwide, the development of antithrombotic agents is a global medical priority. They are subdivided into antiplatelet agents and anticoagulants. Antiplatelet agents inhibit clot formation by preventing platelet activation and aggregation, while anticoagulants primarily inhibit the coagulation cascade and fibrin formation. Therapeutics within each category differs with respect to the mechanism of action, time to onset, duration of effect and route of administration. In this review, we critically discuss their main pharmacodynamic and pharmacokinetic characteristics as well as recent advances in daily clinical practice. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Anticoagulants; antidotes; antiplatelet agents; factor Xa; thrombin; thrombosis

Mesh：

Substances：

Year:  2017        PMID： 28120727     DOI： 10.2174/1381612823666170124141806

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


  3 in total

1.  Hemostatic function to regulate perioperative bleeding in patients undergoing spinal surgery: A prospective observational study.

Authors:  Atsushi Kimura; Tsukasa Ohmori; Asuka Sakata; Teruaki Endo; Hirokazu Inoue; Satoshi Nishimura; Katsushi Takeshita
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

2.  Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib.

Authors:  Despoina Pantazi; Nikoleta Ntemou; Alexios Brentas; Dimitrios Alivertis; Konstantinos Skobridis; Alexandros D Tselepis
Journal:  Drug Des Devel Ther       Date:  2019-12-12       Impact factor: 4.162

3.  Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events.

Authors:  Kallirroi Kalantzi; Nikolaos Tentolouris; Andreas J Melidonis; Styliani Papadaki; Michail Peroulis; Konstantinos A Amantos; George Andreopoulos; George I Bellos; Dimitrios Boutel; Magdalini Bristianou; Dimitrios Chrisis; Nikolaos A Dimitsikoglou; John Doupis; Chrysoula Georgopoulou; Stergios A Gkintikas; Styliani Iraklianou; Κonstantinos Kanellas; Kalliopi Kotsa; Theocharis Koufakis; Maria Kouroglou; Anastasios G Koutsovasilis; Leonidas Lanaras; Eirini Liouri; Charalampos Lixouriotis; Akrivi Lykoudi; Efthymia Mandalaki; Evanthia Papageorgiou; Nikolaos Papanas; Spyridon Rigas; Maria I Stamatelatou; Ioannis Triantafyllidis; Aikaterini Trikkalinou; Aikaterini N Tsouka; Ourania Zacharopoulou; Christos Zoupas; Ioannis Tsolakis; Alexandros D Tselepis
Journal:  J Am Heart Assoc       Date:  2020-12-17       Impact factor: 5.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.